戚智冬,杨斯博,郜杨. 镇痛镇静治疗的脏器保护作用[J]. 中国急救医学, 2019, 39(9): 908-912.
Qi Zhi-dong, Yang Si-bo, Gao Yang. The protection effect of organ function of analgesic and sedative therapy. Chinese Journal of Critical Care Medicine, 2019, 39(9): 908-912.
[1]中华医学会重症医学分会.中国成人ICU镇痛和镇静治疗指南[J].中华重症医学电子杂志,2018,4(2):90-113.
[2]Novaes MA, Knobel E, Bork AM, et al. Stressors in ICU:perception of the patient, relatives and health care team[J]. Intensive Care Med, 1999, 25(12):1421-1426.
[3]Shehabi Y, Chan L, Kadiman S, et al. Sedation depth and long-term mortality in mechanically ventilated critically ill adults: a prospective longitudinal multicenter cohort study[J]. Intensive Care Med, 2013, 39(5):910-918.
[4]Schultz JE, Rose E, Yao Z, et al. Evidence for involvement for involvement of opioid receptors in ischemic preconditioning in rat heart[J]. Am J Physiol, 1995, 268(5-2):H2157-H2161.
[5]Bell SP, Ssek MN, Patel A, et al. Delta opioid receptors stimulation mimics ischemic preconditioning in human heart muscle[J]. J Am Coll Cardiol, 2000, 36(7):2296-2302.
[6]Schultz J el-J, Hsu AK, Nagase H, et al. TAN 67, α-delta 1-opioid receptor agonist, reduces infarct size via activation of Gi/o proteins and K-ATP channels[J]. Am J Physiol, 1998, 274(3):H909-H914.
[7]Miki T, Cohen MV, Downey JM. Opioid receptor contributes to ischemic preconditioning through PKC activation in rabbits[J]. Mol Cell Biochem, 1998, 186(1-2):3-12.
[8]Miura T, Yano T, Naitoh K, et al. Delta-opioid receptor activation before ischemia reduces gap junction permeability in ischemic myoeanlium by PKC mediated phosphorylation of connexin 43[J]. Am J Physiol Heart Cire Physiol, 2007, 293(3):H1425-H1431.
[9]Yiru Guo, Adam B. Stein, Wen-jian Wu, et al. Late precondition induced by NO donors adensine A1 receptor agonists and δopioid receptor agonists is mediated by Inos[J]. Am J Physial Heart Cire Physiol, 2005, 289:H2251-H2257.
[10]Schultz JE, Hsu AK, Gross GJ. Morphine minics the cardioprotective effect of ischemic preconditioning via a glibenclam idesensitive mechanism in the rat heart[J]. Circ Res, 1996, 78(6):1100-1104.
[11]Szekeres L, Papp JG, Szilvássy Z, et al. Moderate stress by cardiac pacing may induce both short and long term cardioprotectron[J]. Cardiovas Res, 1993, 27(4):593-596.
[12]Benedict PE, Benedict MB, Su TP, et al. Opiate drups and delta-receptor-medicated myocardial protection[J]. Circulation, 1999, 100(19):11357-11360.
[13]Kobayashi I, Kokita N, Namiki A. Propofol attenuates ischemia-reperfusion injuru in the rat heart in vivo[J]. Eur J Anaesthesiol, 2008, 25(2):144-151.
[14]Cohen MV, Yang XM, Downey JM. Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning, s success[J]. Basic Res Cardiol, 2008, 103(5):464-471.
[15]Clarke SJ, Khaliulin I, Das M, et al. Inhibition of mitochondrial permeability transition pore opening by ischemic preconditioning is probably mediated by reduction of oxidative stress rather than mitochondrial protein phosphorylation[J]. Circ Res, 2008, 102(9):1082-1090.
[16]杨引,徐军发,刘新,等.丙泊酚对缺血-再灌注心肌细胞凋亡及NF-kB表达的影响[J].临床麻醉学杂志, 2005, 21(10):711-712.
[17]方向东,张云云.丙泊酚预处理对大鼠心肌缺血-再灌注损伤心肌细胞膜ATP酶活性的影响[J].临床麻醉学杂志, 2009, 25(5):433-434.
[18]Okada H, Kurita T, Mochizuki T, et al. The cardioprotective effect of dexmedetomidine on global ischaemia in isolated rat hearts[J]. Resuscitation, 2007, sep:74(3):538-545.
[19]Wang J, Yang X, Camporesi CV, et al. Propofol reduces infarct size and striatal dopamine sccumulation following transient middle cerebral artery occulusion:a microdialysis study[J]. Eur J Phamacol, 2002, 452(3):303-308.
[20]Adembri C, Venturi L, Tani A, et al. Neuroprotective effects of propofol in models of cerebral ischemia:inhibition of mitochondrial swelling as a possible mechanism[J]. Anesthesiology, 2006, 104(1):80-89.
[21]Zheng YY, Lan YP, Tang HF, et al. Propofol pretreatment attenuates aquaporin-4 over-expression and alleviates cerebral edema after transient focal brain ischemia reperfusion in rats[J]. Anesth Analg, 2008, 107(6):2009-2016.
[22]Hoffman WE, Baughman VL, Albrecht RF. Interaction of catecholamines and nitrous oxide ventilation during incomplete brain ischemic in rats[J]. Anesth Analg, 1993, 77(5):908-912.
[23]汪飞. 右美托咪啶对脏器功能保护作用分析[J]. 世界最新医学信息文摘, 2016, 16(12):116-117.
[24]卜林,陈艳. 盐酸右美托咪啶对缺血再灌注肾损伤小鼠的肾小管保护作用[J].中国现代医学杂志, 2016, 26(10):1-5.〖JP〗
[25]Sugita S, Okabe T, Sakamoto A. Continuous infusion of dexmedetomidine improves Renal ischemia-reperfusion injury in rat kidney[J]. J Nippon Med Sch, 2013, 80(2):131-139.
[26]李金洁,康吉龙,赵英,等.右美托咪啶对脓毒症大鼠肾功能及紧密连接蛋白表达的影响[J].中国比较医学杂志, 2016, 26(4):14-17, 45.
[27]雷安锋,段晶,陈燕,等.右美托咪啶对脂多糖致伤大鼠肾小管上皮细胞TLR4表达的影响[J].陕西医学杂志, 2015, 44(9):1112-1113.
[28]王晓军,施燕飞,徐连生,等.右美托咪啶对体外循环心脏瓣膜置换术后肾功能的影响[J].重庆医学, 2017, 46(24):3336-3338, 3342.
[29]张宇,李兵,杜伟忠,等.右美托咪啶对肝移植手术中肾功能的影响[J].临床麻醉学杂志, 2016, 32(2):130-133.
[30]刘瑶,李冰,吴亚辉,等.右美托咪啶对异体肾移植患者围术期肾功能的影响[J].临床麻醉学杂志, 2017, 33(8):751-754.
[31]徐晓燕,吴畏.不同剂量右美托咪啶对妇科恶性肿瘤腹腔镜手术围术期肾功能的影响[J].四川医学, 2015, 36(11):1549-1552.
[32]陈艳红,孙莹杰,张毅男,等.右美托咪啶对感染性休克患者肾损伤分子-1和炎症因子的影响[J].临床军医杂志, 2015, 43(11):817-820.
[33]赵添寿.右美托咪啶的肾保护作用及其机制的研究进展[J].大众科技, 2018, 20(1):63-66.
[34]雷亚娟,马平,梁宇杰.丙泊酚对大鼠缺血再灌注肾TNF-α、NF-κB表达的影响[J].实用骨科杂志, 2007, 13(6):340-343.
[35]林健清,林财珠,蔡宏达.丙泊酚对大鼠肾缺血-再灌注期血清白细胞介素-8的影响[J].临床麻醉学杂志, 2005, 21(6):402-404.
[36]Murphy PG, Myers DS, Davies MJ, et al. The antioxidant potential of propofol(2, 6-diisopropylphenol)[J].Br J Anesth, 1992, 68(6):613-618.
[37]丁宁,肖慧,许立新,等.异丙酚对脂多糖诱导肺泡巨噬细胞高迁移率族蛋白B1启动子转录活性的影响[J].中华急诊医学杂志, 2010, 19(2):156-160.
[38]袁苑,曹定睿,殷渊,等.丙泊酚对大鼠肠缺血再灌注时肝损伤及Bcl-2、Bax蛋白表达的影响[J].山西医科大学学报, 2008, 39(9):791-793.
[39]中华医学会重症医学分会.中国重症加强治疗病房患者镇痛和镇静治疗指导意见(2006)[J].中华外科杂志, 2006, 44(17):1158-1166.